GRANULES vs NATCOPHARM: Stock Comparison

GRANULES INDIA vs NATCO PHARMAUpdated 8 Oct 26, 4:08 PM ISTNSE & company filings

GRANULES INDIA is the larger company by market capitalisation. GRANULES INDIA shows faster revenue growth, while NATCO PHARMA shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

GRANULES leads 5; NATCOPHARM leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

GRANULESNATCOPHARM

Valuation lens

What price are you paying?

Market CapContext only
₹22,150 Cr
₹14,257 Cr
P/E RatioNATCOPHARM has the lower reading
30.11x
12.46x ✓
P/B RatioNATCOPHARM has the lower reading
3.96x
1.55x ✓
EPSGRANULES has the higher reading
₹27.21 ✓
₹4.17
Book ValueContext only
₹205.21
₹514.83
Dividend YieldNATCOPHARM has the higher reading
0.21%
0.55% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
GRANULES is the larger company
₹22,150 Cr vs ₹14,257 Cr
P/E Ratio
NATCOPHARM has a lower P/E
12.46x vs 30.11x
P/B Ratio
NATCOPHARM has a lower P/B
1.55x vs 3.96x
EPS
GRANULES has higher earnings per share
₹27.21 vs ₹4.17
Dividend Yield
NATCOPHARM has a higher dividend yield
0.55% vs 0.21%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs -39.6%
EPS Growth (TTM YoY)
GRANULES has faster EPS growth
31.3% vs -34.1%
Qtr Sales Growth
GRANULES has stronger quarterly sales growth
84.16% vs -18.85%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGRANULESNATCOPHARM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGRANULESNATCOPHARM
Live Price₹815.05₹795.4
Day Change-3.58%-1.81%
Volume6.71 L3.12 L
52-Week High₹923.65₹1,226.8
52-Week Low₹529.85₹792.05
Distance from 52W High-11.76%-35.16%

Valuation

MetricGRANULESNATCOPHARM
Market Cap₹22,150 Cr₹14,257 Cr
P/E Ratio30.11x12.46x
P/B Ratio3.96x1.55x
EPS₹27.21₹4.17
Book Value₹205.21₹514.83
Dividend Yield0.21%0.55%

Growth

MetricGRANULESNATCOPHARM
Revenue Growth (TTM YoY)22.8%-39.6%
EPS Growth (TTM YoY)31.3%-34.1%
Qtr Sales Growth84.16%-18.85%
Qtr Profit Growth150.83%-63.87%

Profitability & Leverage

MetricGRANULESNATCOPHARM
ROE11.7%14.98%
ROCE12.47%14.19%
Net Margin11.15%34.78%
Operating Margin16.76%38.85%
Debt to Equity0.26x0.08x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricGRANULESNATCOPHARM
Promoter Holding37.08%▼ 0.59 pp49.14%
FII Holding20.29%▲ 2.79 pp16.99%▼ 0.38 pp
DII Holding15.4%▼ 0.71 pp5.62%▲ 0.16 pp
Public Holding26.93%▼ 1.45 pp27.97%▲ 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GRANULES INDIA and NATCO PHARMA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.